依普利酮治疗活动性、既往未治疗超过4个月的慢性中心性浆液性脉络膜视网膜病变(VICI):随机双盲安慰剂对照试验
VICI是一项在英国22家医院开展的随机、双盲、平行组、多中心安慰剂对照试验,纳入18-60岁、未经治疗且病程≥4个月的慢性CSCR患者114例,1:1随机接受口服依普利酮(25 mg/d 1周后增至50 mg/d,最长12个月)加常规护理或安慰剂加常规护理。主要终点为12个月时BCVA(读出的字母数)。结果显示,12个月时模型估计平均BCVA安慰剂组79.5个字母(SD 4.5)vs 依普利酮组80.4个字母(4.6),校正估计平均差异1.73个字母(95%CI -1.12至4.57;p=0.24),依普利酮不优于安慰剂。两组高钾血症各8例(14%);依普利酮组无严重不良事件,安慰剂组报告3例无关严重不良事件。作者结论认为依普利酮对慢性CSCR的BCVA无优势,眼科医生应停止为CSCR处方依普利酮。
要点
- 慢性CSCR患者口服依普利酮(25 mg/d 1周后增至50 mg/d,最长12个月)12个月时BCVA不优于安慰剂:校正估计平均差异1.73个字母(95%CI -1.12至4.57;p=0.24)。
- 12个月时模型估计平均BCVA:安慰剂组79.5个字母(SD 4.5)vs 依普利酮组80.4个字母(4.6)。
- 高钾血症在依普利酮组和安慰剂组各发生8例(14%)。
- 依普利酮组无严重不良事件;安慰剂组报告3例无关严重不良事件(心肌梗死[预期]、憩室炎[非预期]、代谢手术[非预期])。
- 作者结论:依普利酮对慢性CSCR的BCVA无优势,目前为CSCR处方依普利酮的眼科医生应停止这一做法。
适用人群与场景
- 年龄18-60岁、患有未经治疗的慢性CSCR且病程≥4个月的患者。
处置流程与药物剂量
- 依普利酮组:口服依普利酮25 mg/d持续1周,随后增至50 mg/d,最长12个月,同时接受常规护理。
- 安慰剂组:口服安慰剂加常规护理,最长12个月。
研究设计与关键结果
- 研究类型:随机、双盲、平行组、多中心安慰剂对照试验,在英国22家医院开展;2017年1月11日至2018年2月22日纳入并随机分配114例患者至依普利酮组(n=57)或安慰剂组(n=57)。
- 主要终点分析人群:依普利酮组57例全部纳入,安慰剂组54例纳入(3例安慰剂组患者撤回知情同意且未提供随机后BCVA测量而被排除)。
- 主要终点:12个月时模型估计平均BCVA安慰剂组79.5个字母(SD 4.5)vs 依普利酮组80.4个字母(4.6),校正估计平均差异1.73个字母(95%CI -1.12至4.57;p=0.24),依普利酮不优于安慰剂。
- 不良事件:高钾血症在依普利酮组和安慰剂组各8例(14%);依普利酮组无严重不良事件,安慰剂组报告3例无关严重不良事件(心肌梗死[预期]、憩室炎[非预期]、代谢手术[非预期])。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验(RCT)。
- 作者结论:依普利酮在治疗12个月后对慢性CSCR患者的BCVA不优于安慰剂;作者认为目前为CSCR处方依普利酮的眼科医生应停止这一做法。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,目前为CSCR处方依普利酮的眼科医生应停止这一做法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In chronic central serous chorioretinopathy (CSCR), fluid accumulates in the subretinal space. CSCR is a common visually disabling condition that develops in individuals up to 60 years of age, and there is no definitive treatment. Previous research suggests the mineralocorticoid receptor antagonist, eplerenone, is effective for treating CSCR; however, this drug is not licensed for the treatment of patients with CSCR. We aimed to evaluate whether eplerenone was superior to placebo in terms of improving visual acuity in patients with chronic CSCR.
METHODS: This randomised, double-blind, parallel-group, multicentre placebo-controlled trial was done at 22 hospitals in the UK. Participants were eligible if they were aged 18-60 years and had had treatment-naive CSCR for 4 months or more. Patients were randomly assigned (1:1) to either the eplerenone or the placebo group by a trial statistician through a password-protected system online. Allocation was stratified by best-corrected visual acuity (BCVA) and hospital. Patients were given either oral eplerenone (25 mg/day for 1 week, increasing to 50 mg/day for up to 12 months) plus usual care or placebo plus usual care for up to 12 months. All participants, care teams, outcome assessors, pharmacists, and members of the trial management group were masked to the treatment allocation. The primary outcome was BCVA, measured as letters read, at 12 months. All outcomes apart from safety were analysed on a modified intention-to-treat basis (participants who withdrew consent without contributing a post-randomisation BCVA measurement were excluded from the primary analysis population and from most secondary analysis populations). The trial is registered with ISRCTN, ISRCTN92746680, and is completed.
FINDINGS: Between Jan 11, 2017, and Feb 22, 2018, we enrolled and randomly assigned 114 patients to receive either eplerenone (n=57) or placebo (n=57). Three participants in the placebo group withdrew consent without contributing a post-randomisation BCVA measurement and were excluded from the primary outcome analysis population. All patients from the eplerenone group and 54 patients from the placebo group were included in the primary outcome. Modelled mean BCVA at 12 months was 79·5 letters (SD 4·5) in the placebo group and 80·4 letters (4·6) in the eplerenone group, with an adjusted estimated mean difference of 1·73 letters (95% CI -1·12 to 4·57; p=0·24) at 12 months. Hyperkalaemia occurred in eight (14%) patients in each group. No serious adverse events were reported in the eplerenone group and three unrelated serious adverse events were reported in the placebo group (myocardial infarction [anticipated], diverticulitis [unanticipated], and metabolic surgery [unanticipated]).
INTERPRETATION: Eplerenone was not superior to placebo for improving BCVA in people with chronic CSCR after 12 months of treatment. Ophthalmologists who currently prescribe eplerenone for CSCR should discontinue this practice.
FUNDING: Efficacy and Mechanism Evaluation Programme, and National Institute for Health Research and Social Care.
参考来源
- Lotery A, Sivaprasad S, O'Connell A, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020. PMID: 31982075. doi:10.1016/S0140-6736(19)32981-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。